
WHAT IS CLAIMED IS

1. The (*S*)-enantiomer of 1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-*f*][1,3]benzodioxole-7,3'-indol]-2'(1'*H*)-one having the following formula (I-*S*):



(I-*S*)

;

or a pharmaceutically acceptable solvate or prodrug thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the (*S*)-enantiomer of Claim 1, or a pharmaceutically acceptable solvate or prodrug thereof.

3. A method of treating a disease or a condition in a mammal selected from the group consisting of pain, depression, cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases and seizures, and combinations thereof, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of the (*S*)-enantiomer of Claim 1, or a pharmaceutically acceptable solvate or prodrug thereof.

4. The method of Claim 3, wherein said disease or condition is selected from the group consisting of neuropathic pain, inflammatory pain, visceral pain, cancer pain, dental pain, chemotherapy pain, trauma pain, surgical pain, labor pain, neurogenic bladder, ulcerative colitis, chronic pain, persistent pain, peripherally mediated pain, centrally mediated pain, chronic headache, migraine headache, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, and combinations thereof.

5. The method of Claim 3, wherein said disease or condition is selected from the group consisting of pain associated with HIV, HIV treatment induced

neuropathy, trigeminal neuralgia, post-herpetic neuralgia, eudynia, heat sensitivity, sarcoidosis, irritable bowel syndrome, Crohns disease, pain associated with multiple sclerosis, amyotrophic lateral sclerosis, pruritis, hypercholesterolemia, benign prostatic hyperplasia, diabetic neuropathy, peripheral neuropathy, arthritic, rheumatoid arthritis, osteoarthritis, paroxysmal dystonia, myasthenia syndromes, myotonia, malignant hyperthermia, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, bipolar depression, anxiety, schizophrenia, sodium channel toxin related illnesses, familial erythermalgia, primary erythromelalgia, familial rectal pain, Paroxysmal Episodic Pain Disorder, cancer, epilepsy, partial and general tonic seizures, restless leg syndrome, arrhythmias, fibromyalgia, neuroprotection under ischaemic conditions caused by stroke or neural trauma, tachy-arrhythmias, atrial fibrillation and ventricular fibrillation.


6. A method of treating a disease or condition in a mammal by the inhibition of ion flux through a voltage-gated sodium channel in the mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of the (*S*)-enantiomer of Claim 1, or a pharmaceutically acceptable solvate or prodrug thereoff.

7. A method of decreasing ion flux through a voltage-gated sodium channel in a cell in a mammal, wherein the method comprises contacting the cell with the (*S*)-enantiomer of Claim 1, or a pharmaceutically acceptable solvate or prodrug thereof.

8. The use of the (*S*)-enantiomer of Claim 1 in the preparation of a medicament for the treatment of a disease or condition ameliorated or alleviated by the inhibition of a voltage-gated sodium channel in mammal.

What is claimed is:

1. The (*S*)-enantiomer of 1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-*f*][1,3]benzodioxole-7,3'-indol]-2'(1'*H*)-one having the following formula (I-*S*):



(I-*S*)

2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the (*S*)-enantiomer of Claim 1.